2017 American Transplant Congress
Early Results of Immune Profile Emerging Before Detection of De Novo Humoral Alloimmunity in Kidney Transplant Recipients.
The purpose of this IRB-approved study is to determine if there is a potential role for CD8+ T cell-mediated suppression of donor specific alloantibody (DSA)…2017 American Transplant Congress
Outcome of ABO-Incompatible Kidney Transplantation After Stratified Desensitization.
Background. Plasmapheresis for antibody removal and rituximab for antibody production suppression are performed for desensitization against ABO-incompatible kidney transplantation. We evaluated clinical outcome for optimizing…2017 American Transplant Congress
Bortezomib for Late Antibody-Mediated Rejection After Renal Transplantation: A Single Center Experience of 22 Cases.
Despite of tradifional treatments for AMR, such as plasapheresis, ingravenous immunoglobulin, and rituximab, current treatment for antibody-mediated rejection(AMR) after renal transplantation is insufficient. Recently, Bortezomib…2017 American Transplant Congress
Donor-Derived Cell-Free DNA Parallels Increases in Donor Specific Antibodies in Pediatric Kidney Transplant Recipients.
1Surgery, Stanford University, Palo Alto, CA; 2CareDx, Brisbane, CA
Introduction: Anti-HLA antibody screening is a critical component of post-kidney transplant surveillance. Existing protocols and treatment plans are not standard/consistent across institutions. As increasing numbers…2017 American Transplant Congress
Reduced Conversion from IgM Anti-HLA-DSA to IgG Anti-HLA-DSA in Belatacept-Treated vs. Cyclosporine-Treated Patients in BENEFIT and BENEFIT-EXT Trials.
Post-transplant, up to 50% of recipients develop IgM DSA. Half of these patients go on to develop IgG DSA. Importantly, patients that progress to IgG…2017 American Transplant Congress
CD8+ TAb-supp Cells Suppress the Production of Multiple Alloantibody Isotypes in Response to MHC-Mismatched Cellular and Vascularized Allografts.
Surgery, The Ohio State University Wexner Medical Center, Columbus, OH
We have reported that a CD8+ T cell subset, we termed CD8+ TAb-supp cells, inhibits the production of alloAb after hepatocyte transplant (HcTx) in part…2017 American Transplant Congress
De Novo DSA Positivity Is Associated with a Higher Rate of Post-Transplant Bacterial and Viral Infections.
Background: BK viremia has been shown to correlate with de novo anti-HLA DSA (dnDSA) in renal transplant patients. However, it is unknown if and how…2017 American Transplant Congress
Long-Term Persistence of Anti-HLA Antibodies in Renal Trasplant Recipients: Risk Factors and Impact on Clinical Course.
Objectives:1) To evaluate the incidence of development of anti-HLA antibodies on the long run in our renal transplant population and the main risk factors for…2017 American Transplant Congress
Assessment of C4d Positive Biopsies with No Histological Evidence of Inflammation Using Nanostring nCounter Technology.
Deposition of C4d has been an established part of the Banff classification scheme for antibody mediated rejection (AbMR) since 2001. More recently, C4d negative AbMR…2017 American Transplant Congress
Post-Transplant Reduction in Pre-Existing Donor-Specific Antibody Levels After Belatacept- vs Cyclosporine-Based Immunosuppression.
1Emory University, Atlanta, GA; 2Bristol-Myers Squibb, Lawrenceville, NJ
Purpose: We explored the effect of belatacept (bela)- and cyclosporine (CsA)-based immunosuppression (IS) on pre-existing donor-specific antibody (DSA) levels by mean fluorescence intensity (MFI) in…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 57
- Next Page »